Bu sayfanın çevirisi deneyseldir ve geliştirilme aşamasındadır. imlerinizi bekliyoruz!
Mabpharm Yönetim
Yönetim kriter kontrolleri 2/4
We currently do not have sufficient information about the CEO.
Anahtar bilgiler
Hao Wang
İcra Kurulu Başkanı
CN¥5.6m
Toplam tazminat
| CEO maaş yüzdesi | 19.1% |
| CEO görev süresi | 6.2yrs |
| CEO sahipliği | n/a |
| Yönetim ortalama görev süresi | 6.2yrs |
| Yönetim Kurulu ortalama görev süresi | 4yrs |
Son yönetim güncellemeleri
Recent updates
Shareholders May Be A Bit More Conservative With Mabpharm Limited's (HKG:2181) CEO Compensation For Now
Jun 14
More Unpleasant Surprises Could Be In Store For Mabpharm Limited's (HKG:2181) Shares After Tumbling 41%
Jan 24Mabpharm (HKG:2181) Is Making Moderate Use Of Debt
Oct 20Here's Why We're Watching Mabpharm's (HKG:2181) Cash Burn Situation
Jan 18Here's Why We're Watching Mabpharm's (HKG:2181) Cash Burn Situation
Oct 07Here's Why We're Not Too Worried About Mabpharm's (HKG:2181) Cash Burn Situation
Apr 28Did You Miss Mabpharm's (HKG:2181) 14% Share Price Gain?
Mar 03We're Not Very Worried About Mabpharm's (HKG:2181) Cash Burn Rate
Jan 27
Do Insiders Own Lots Of Shares In Mabpharm Limited (HKG:2181)?
Dec 09CEO Tazminat Analizi
| Tarih | Toplam Tazminat | Maaş | Şirket Kazançları |
|---|---|---|---|
| Jun 30 2024 | n/a | n/a | -CN¥207m |
| Mar 31 2024 | n/a | n/a | -CN¥208m |
| Dec 31 2023 | CN¥6m | CN¥1m | -CN¥209m |
| Sep 30 2023 | n/a | n/a | -CN¥202m |
| Jun 30 2023 | n/a | n/a | -CN¥194m |
| Mar 31 2023 | n/a | n/a | -CN¥202m |
| Dec 31 2022 | CN¥3m | CN¥1m | -CN¥211m |
| Sep 30 2022 | n/a | n/a | -CN¥237m |
| Jun 30 2022 | n/a | n/a | -CN¥263m |
| Mar 31 2022 | n/a | n/a | -CN¥278m |
| Dec 31 2021 | CN¥5m | CN¥1m | -CN¥292m |
Tazminat ve Piyasa: Hao's total compensation ($USD795.97K) is above average for companies of similar size in the Hong Kong market ($USD354.63K).
Tazminat ve Kazançlar: Hao's compensation has increased whilst the company is unprofitable.
CEO
Hao Wang (55 yo)
6.2yrs
Görev süresi
CN¥5,596,000
Tazminat
Dr. Hao Wang serves as Chief Executive Officer and Executive Director at Mabpharm Limited since October 28, 2020 and July 20, 2018 respectively and also serves as Chief Scientist since August 2018. Dr. Wan...
Liderlik Ekibi
| İsim | Pozisyon | Görev süresi | Tazminat | Sahiplik |
|---|---|---|---|---|
| Chief Scientist | 6.2yrs | CN¥5.60m | Veri yok | |
| VP & Executive Director | no data | CN¥1.54m | Veri yok | |
| VP & Executive Director | less than a year | CN¥70.00k | Veri yok | |
| VP & Executive Director | less than a year | CN¥445.00k | Veri yok | |
| VP, Joint Company Secretary & Executive Director | 6.2yrs | CN¥1.58m | Veri yok | |
| Vice President | 6.2yrs | CN¥1.40m | Veri yok | |
| Joint Company Secretary | no data | Veri yok | Veri yok |
6.2yrs
Ortalama Görev Süresi
48yo
Ortalama Yaş
Deneyimli Yönetim: 2181's management team is seasoned and experienced (6.2 years average tenure).
Yönetim Kurulu Üyeleri
| İsim | Pozisyon | Görev süresi | Tazminat | Sahiplik |
|---|---|---|---|---|
| Chief Scientist | 6.3yrs | CN¥5.60m | Veri yok | |
| VP & Executive Director | 4yrs | CN¥1.54m | Veri yok | |
| VP & Executive Director | less than a year | CN¥70.00k | Veri yok | |
| VP & Executive Director | less than a year | CN¥445.00k | Veri yok | |
| VP, Joint Company Secretary & Executive Director | 6.3yrs | CN¥1.58m | Veri yok | |
| Non-Executive Chairman | 6.3yrs | Veri yok | Veri yok | |
| Independent Non-Executive Director | 6.2yrs | CN¥108.00k | Veri yok | |
| Independent Non-Executive Director | 6.2yrs | CN¥108.00k | Veri yok | |
| Independent Non-Executive Director | 2.3yrs | CN¥108.00k | Veri yok | |
| Non-Executive Director | less than a year | Veri yok | Veri yok | |
| Independent Non-Executive Director | less than a year | Veri yok | Veri yok |
4.0yrs
Ortalama Görev Süresi
51yo
Ortalama Yaş
Deneyimli Yönetim Kurulu: 2181's board of directors are considered experienced (4 years average tenure).